CytoDyn stock investors went through a wild roller coaster ride witnessing it’s price per share downfall since the beginning of August. Current CYDY stock is traded at OTC Markets as low as $0.45, that means dangerous waters would be tested within September.
Some retail investors believe in CytoDyn biotech company due to unrivaled products derived from HIV and Cancer research labs. Most important entity being Leronlimab (Pro 140) antibody medicine with CCR5 immunologic receptor. Nonetheless, this product is still under strong research focus.
Interestingly, CytoDyn may have fallen hard this year caused by FDA’s warning letter claiming that Leronlimab’s video presentation has a misleading impression concerning it’s safety and efficacy.
However, the appointment of new president Cyrus Arman, Ph.D., MBA with 15 years of experience had boosted surging stock price by up to 50% in July. By far, $0.50 price territory was an average throughout a year amid some disputes erupted with it’s former CMO too.
Would anybody invest in stagnant CYDY stock during high inflation times? Some may hit lucky trading day if CYDY surges upwards if Leronlimab is approved by prominent institutions. Dangerous waters seem not so deep for loyal CYDY investors who trust new President with PhD title.